Engineered macrophages take on Hard-to-Treat cancers

NCT ID NCT07409766

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a new type of cell therapy called CAR-Macrophages in 20 adults with advanced solid tumors. The immune cells are modified to target specific markers on cancer cells (HER2, PSMA, FAP) and are given by IV. The main goals are to check safety, find the best dose, and see if the cells can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
CAR-Macrophage cells (genetically modified immune cells targeting HER2, PSMA, FAP)
What this could lead to
If successful, this could point toward a new cell therapy for advanced solid tumors that are hard to treat with current options.
What could go wrong
This is a very early (Phase 1) trial with only 20 participants, so safety and effectiveness are not yet proven. The therapy may cause severe side effects like cytokine storms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences

    Beijing, 100000, China

    Contact Phone: •••-•••-••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.